{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:10:06Z","timestamp":1787062206291,"version":"build-2736575974"},"reference-count":260,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: A number of viruses are oncogenic. These include the human papilloma virus (HPV), Epstein\u2013Barr virus (EBV), Kaposi sarcoma human herpes virus 2\/human herpes virus 8 (KSHHV\/HHV8), hepatitis B virus, (HBV), hepatitis C virus (HCV), Merkel cell polyoma virus (McPyV), and the human T-cell leukemia virus type 1 (HTLV-1). These viruses cause malignancies ranging from carcinomas, sarcomas, lymphomas, to leukemias. This review aims to study the effects and efficacy of vaccines against these viruses and the cancers they cause in their prevention and treatment. Methods: The literature in the past 30 years was searched employing Scopus and Google Scholar using the keywords \u201concogenic viruses, HPV, EBV, KSHHV, HHV8, Polyoma virus, HTLV-1, COVID-19, carcinoma, sarcoma, lymphoma, leukemia, anti-virus vaccines\u201d. Results: Prophylactic vaccines against the HPV and HBV are highly effective in preventing and reducing the incidence of uterine cervical and hepatocellular carcinomas. Prophylactic vaccines against other oncogenic viruses have been less successful, though efficacious in some experimental animals. Therapeutic vaccines are still mostly under evaluation and development. Conclusions: Identification of oncogenic viruses has rendered anti-viral vaccines conspicuous tools for preventing and treating cancers they cause. Many endeavors for the development of such vaccines have been met with limited success, apart from the very effective anti-HPV and anti-HBV vaccines in universal vaccination programs. With the development of new vaccine technologies, it is hoped that effective vaccines against other oncogenic viruses will be developed in the future.<\/jats:p>","DOI":"10.3390\/vaccines13090911","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:29:18Z","timestamp":1756376958000},"page":"911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy of Oncovirus-Induced Cancers: A Review on the Development and Efficacy of Targeted Vaccines"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-5479","authenticated-orcid":false,"given":"Chi Sing","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Pathology, Caritas Medical Center, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global Burden of Cancer Attributable to Infections in 2018: A Worldwide Incidence Analysis","volume":"8","author":"Georges","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The Global Health Burden of Infection-associated Cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.3390\/v6104047","article-title":"Human Viruses and Cancer","volume":"6","year":"2014","journal-title":"Viruses"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","article-title":"Viral Oncogenesis in Cancer: From Mechanisms to Therapeutics","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102253","DOI":"10.1016\/j.coi.2022.102253","article-title":"oncogenic Viruses, Cancer Biology and Innate Immunity","volume":"78","author":"White","year":"2023","journal-title":"Curr. Opin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coviro.2018.09.003","article-title":"More than just Oncogenes: Mechanisms of Tumorigenesis by Human Viruses","volume":"32","author":"Gaglia","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.pathol.2024.07.002","article-title":"From the Midfacial Destructive Drama to the Unfolding EBV Story: A Short History of EBV-positive NK-cell and T-cell lymphoproliferative Diseases","volume":"56","author":"Ng","year":"2024","journal-title":"Pathology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107025","DOI":"10.1016\/j.micpath.2024.107025","article-title":"The role of C-MYC in Epstein-Barr Virus-associated Cancers: Mechanistic Insights and Therapeutic Implications","volume":"197","author":"Mahdavi","year":"2024","journal-title":"Microb. Pathog."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semcancer.2009.07.007","article-title":"How does Epstein-Barr Virus (EBV) Complement the Activation of Myc in the Pathogenesis of Burkitt\u2019s Lymphoma?","volume":"19","author":"Allday","year":"2009","journal-title":"Semin. Cancer Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nrc2961","article-title":"Why do viruses cause cancer? Highlights of the First Century of Human Tumour Virology","volume":"10","author":"Moore","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000252780","article-title":"Impacts of Vaccination on Hepatitis B Viral Infections in Korea over a 25-year Period","volume":"53","author":"Park","year":"2010","journal-title":"Intervirology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrmicro2872","article-title":"Understanding and Learning from the Success of Prophylactic Human Papillomavirus Vaccines","volume":"10","author":"Schiller","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr Virus: An Important Vaccine target for Cancer Prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41541-022-00535-4","article-title":"KSHV (HHV8) Vaccine: Promises and Potential Pitfalls for a New Anti-cancer Vaccine","volume":"7","author":"Casper","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ghattas, M., Dwivedi, G., Lavertu, M., and Alameh, M.G. (2021). Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges and Opportunities. Vaccines, 9.","DOI":"10.3390\/vaccines9121490"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic Cancer Vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pbiomolbio.2023.02.004","article-title":"An Overview of the Vaccine Platforms to Combat COVID-19 with a focus on the Subunit Vaccines","volume":"178","author":"Bayani","year":"2023","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Folorunso, O.S., and Sebolai, O.M. (2020). Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines. Vaccines, 8.","DOI":"10.3390\/vaccines8030341"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nm1726","article-title":"Engineering Attenuated Virus Vaccines by Controlling Replication Fidelity","volume":"14","author":"Vignuzzi","year":"2008","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107586","DOI":"10.1016\/j.celrep.2020.107586","article-title":"Mechanism of Virus Attenuation by Codon Pair Deoptimization","volume":"31","author":"Groenke","year":"2020","journal-title":"Cell Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mak, T.W., and Saunders, M.E. (2006). Vaccines and Clinical Immunization. The Immune Response, Academic Press.","DOI":"10.1016\/B978-012088451-3\/50025-9"},{"key":"ref_22","first-page":"71085","article-title":"Era Vaccine-derived Cases of Rabies in Wildlife and Domestic Animals in Ontario, Canada, 1989\u20132004","volume":"44","author":"Armstrong","year":"2008","journal-title":"J. Wildl. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Frederiksen, L.S.F., Zhang, Y., Foged, C., and Thakur, A. (2020). The Long road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01817"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1134\/S0026893319030154","article-title":"Virus-like Particles as an Instrument of Vaccine Production","volume":"53","author":"Syomin","year":"2019","journal-title":"Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for Virus-like Particle (VLP) Based Vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering Virus-like Particles as Vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1590\/S1517-83822014000400001","article-title":"Live Bacteria Vaccine Vectors: An Overview","volume":"45","author":"Zangirolami","year":"2014","journal-title":"Braz. J. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel Viral Vectors in Infectious Diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","article-title":"Viral Vectors as Vaccine Carriers","volume":"21","author":"Ertl","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/17425247.2016.1121990","article-title":"Clinical Potential of Electroporation for Gene Therapy and DNA Vaccine Delivery","volume":"13","author":"Lambricht","year":"2016","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.gt.3302213","article-title":"Detection of Integration of Plasmid DNA into Host Genomic DNA Following Intramuscular Injection and Electroporation","volume":"11","author":"Wang","year":"2004","journal-title":"Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Alameh, M.-G., Weissman, D., and Pardi, N. (2020). Messenger RNA-Based Vaccines Against Infectious Diseases, Springer.","DOI":"10.1007\/82_2020_202"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA Outperforms Pseudouridine-incorporated mRNA by Providing Enhanced Protein Expression and Reduced Immunogenicity in Mammalian Cell Lines and Mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA Vaccines for Infectious Diseases. Principles, Delivery and Clinical Translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J.B., De Gregorio, E., Geall, A.J., Brazzoli, M., and Bertholet, S. (2016). Self-amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection Against Homologous and Heterosubtypic Viral Challenge. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161193"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The Biogenesis, Biology and Characterization of Circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid Nanoparticles Enhance the Efficacy of mRNA and Protein Subunit Vaccines by Inducing Robust T Follicular Helper Cell and Humoral Responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature18945","article-title":"Neoantigen Landscape Dynamics During Human Melanoma-T Cell Interactions","volume":"536","author":"Verdegaal","year":"2016","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to Checkpoint Blockade Therapy through Inactivation of Antigen Presentation","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","article-title":"In situ Vaccination: Cancer Immunotherapy both Personalized and Off-the-shelf","volume":"9","author":"Hammerich","year":"2015","journal-title":"Mol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta Attenuates Tumor Response to PD-L1 Blockade by Contributing to Exclusion of T Cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","article-title":"Resistance to Radiotherapy and PD-L1 Blockade is Mediated by TIM-3 Upregulation and regulatory T-cell Infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","article-title":"Shared Immunogenic Poly-epitope Frameshift Mutations in Microsatellite Unstable Tumors","volume":"183","author":"Roudko","year":"2020","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e000262","DOI":"10.1136\/jitc-2019-000262","article-title":"MHC-restricted Phosphopeptide Antigens: Preclinical Validation and First-in-humans Clinical Trial in Participants with High-risk Melanoma","volume":"8","author":"Engelhard","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101393","DOI":"10.1016\/j.smim.2020.101393","article-title":"Post-translational Modifications such as Citrullination are Excellent Targets for Cancer Therapy","volume":"47","author":"Brentville","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e126908","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 Expression and Tumor Mutational Burden are Independent Biomarkers in Most Cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13073-019-0697-8","article-title":"Neoantigen-specific Immunity in Low Mutation Burden Colorectal Cancers of the Consensus Molecular Subtype 4","volume":"11","author":"Verdegaal","year":"2019","journal-title":"Genome Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA Vaccine Drives Immunity in Checkpoint-inhibitor-treated Melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41590-020-00810-3","article-title":"Intravenous Nanoparticle Vaccination Generates Stem-like TCF1-neoantigen-specific CD8+ T Cells","volume":"22","author":"Baharom","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2017.11.035","article-title":"Hollow Microneedle-mediated Micro-injections of a Liposome HPVE743-63 Synthetic Long Peptide Vaccine for Efficient Induction of Cytotoxic and T-helper responses","volume":"269","author":"Heuts","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41563-018-0028-2","article-title":"A Facile Approach to Enhance Antigen response for Personalized Cancer Vaccination","volume":"17","author":"Li","year":"2018","journal-title":"Nat. Mater."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/cgt.2013.45","article-title":"Enhancement of Systemic Tumor Immunity for Squamous Cell Carcinoma Cells by an Oncolytic Herpes Simplex Virus","volume":"20","author":"Meshii","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/mt.2012.137","article-title":"An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance","volume":"20","author":"Cerullo","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_55","first-page":"141","article-title":"Different Mechamisms for Anti-tumor Effects of Low-and High-Dose Cyclophosphamide","volume":"16","author":"Motoyoshi","year":"2006","journal-title":"Oncol. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated with Oncolytic Adenovirus","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00262-009-0671-1","article-title":"Treg Depletion with a Low-dose Metronomic Temozolomide Regimen in a Rat Glioma Model","volume":"58","author":"Banissi","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine Adjuvants: Mechanisms and Platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_60","first-page":"787","article-title":"Vaccine Adjuvants: Putting Innate Immunity to Work","volume":"10","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41541-023-00760-5","article-title":"The Advances of adjuvants in mRNA Vaccines","volume":"8","author":"Xie","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.molmed.2024.05.009","article-title":"HPV Integration and Cervical Cancer: A Failed Evolutionary Viral Trait","volume":"30","author":"Molina","year":"2024","journal-title":"Trends Mol. Med."},{"key":"ref_63","unstructured":"(2022, December 16). WHO Vaccine Position Papers. Weekly Epidemiological Record No. 50, 2022, 97, 645\u2013672. World Health Organization. Geneva. Available online: https:\/\/www.who.int\/publications\/i\/item\/who-wer9750-645-672."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2017). Integrated Genomic and Molecular Characterization of Cervical Cancer. Nature, 543, 378\u2013384.","DOI":"10.1038\/nature21386"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"63327","DOI":"10.1038\/s41388-020-01431-8","article-title":"HPV E2, E4, E5 Drive Alternative Carcinogenic Pathways in HPV Positive Cancers","volume":"39","author":"Ren","year":"2020","journal-title":"Oncogene"},{"key":"ref_66","first-page":"1","article-title":"The Role of Hippo-YAP Signaling in Squamous Cell Carcinomas","volume":"20","author":"Maehama","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Basslar, F., Hoppe-Seyler, K., and Hoppe-Seyler, F. (2019). PI3K\/AKT\/mTOR Signaling Regulates the Virus\/Host Cell Crosstalk in HPV-positive Cervical Cancer Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092188"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.pvr.2019.03.005","article-title":"Role of DNA methylation in HPV associated lesions","volume":"7","author":"Prigge","year":"2019","journal-title":"Papillomavirus Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wongjampa, W., Nakahara, T., Tanaka, K., Yugawa, T., Ekalaksananan, T., Kleebkaow, P., Goshima, N., Kiyono, T., and Pientong, C. (2023). An In Vitro Carcinogenesis Model for Cervical Cancer Harboring Episomal form of HPV16. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0281069"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ni, H., Huang, C., Ran, Z., Li, S., Kuang, C., Zhang, Y., and Yuan, K. (2024). Targeting HPV for the Prevention, Diagnosis, and Treatment of Cervical Cancer. J. Mol. Cell. Biol., 16.","DOI":"10.1093\/jmcb\/mjae046"},{"key":"ref_71","unstructured":"Herrington, C.S., and Ordi, J. (2020). Squamous Cell Carcinoma. HPV-associated, of the Uterine Cervix. WHO Classification of Female Genital Tumours, IARC. [5th ed.]."},{"key":"ref_72","unstructured":"Herrington, C.S., and Ordi, J. (2020). Squamous Cell Carcinoma, HPV-independent, of the Uterine Cervix. WHO Classification of Female Genital Tumours, IARC. [5th ed.]."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/1055-9965.EPI-15-0869","article-title":"Prevalence, Clinicopathological Characteristics and Outcome of Human Papillomavirus-associated Oropharyngeal Cancrs in Southern Chinese Patients","volume":"25","author":"Lam","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV Vaccination and the Risk of Invasive Cervical Cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e077341","DOI":"10.1136\/bmj-2023-077341","article-title":"Effect of the HPV Vaccination Programme on Incidence of Cervical Cancer and Grade 3 Cervical Intraepithelial Neoplasia by Socioeconomic Deprivation in England: Population Based Observational Study","volume":"385","author":"Falcaro","year":"2024","journal-title":"BMJ"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2018.05.001","article-title":"Preclinical Development of Oncolytic Immunotherapy for Treatment of HPV-positive Cancers","volume":"10","author":"Suksanpaisan","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s40136-023-00443-8","article-title":"Therapeutic Vaccination for HPV-mediated Cancers","volume":"11","author":"Yan","year":"2023","journal-title":"Curr. Otorhinolaryngol. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000518758","article-title":"Human Immunodeficiency Virus Infection Promotes Human Papillomavirus\u2013mediated Anal Squamous Carcinogenesis: An Immunologic and Pathobiologic Review","volume":"89","author":"Bushara","year":"2022","journal-title":"Pathobiology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/QAD.0000000000001765","article-title":"HIV-positive Women have Higher Risk of Human Papillomavirus Infection, Pecancerous Lesions, and Cervical Cancer","volume":"32","author":"Liu","year":"2018","journal-title":"AIDS"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/COH.0000000000000336","article-title":"Human Papillomavirus-associated Anal and Cervical Cancers in HIV-infected individuals: Incidence and Prevention in the Anti-retroviral Therapy Era","volume":"12","author":"Palefsky","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/spectrum.03622-22","article-title":"HIV-1 proteins gp120 and Tat Promote Epithelial-mesenchymal Transition and Invasiveness of HPV-positive and HPV-negative Neoplastic Genital and Oral Epithelial Cells","volume":"10","author":"Lien","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Isaguliants, M., Bayurova, E., Avodoshina, D., Kondrashova, A., Chiodi, F., and Palefsky, J.M. (2021). Oncogenic Effects of HIV-1 proteins, Mechanisms Behind. Cancers, 13.","DOI":"10.3390\/cancers13020305"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbadis.2008.01.006","article-title":"Role of Transforming Growth Factor-beta Superfamily Signaling Pathways in Human Disease","volume":"1782","author":"Gordon","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1096\/fj.06-7798com","article-title":"Sequential Actions of ERK1\/2 on the AP-1 Transcription Factor Allow Temporal Integration of Metabolic Signals in Pancreatic Beta Cells","volume":"21","author":"Glauser","year":"2007","journal-title":"FASEB J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1128\/AAC.00419-09","article-title":"Antiretroviral Tissue Kinetics: In Vivo Imaging Using Positron Emission Tomography","volume":"53","author":"DiMascio","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Boomgarden, A.C., and Upadhyay, C. (2025). Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview. Vaccines, 13.","DOI":"10.3390\/vaccines13020148"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/JCM.02206-10","article-title":"Shedding of Epstein-Barr Virus and Cytomegalovirus from the Genital Tract of Women in a Periurban Community in Andhra, Pradesh, India","volume":"49","author":"Silver","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1590\/S1517-83822012000200039","article-title":"Correlation Between EBV Co-infection and HPV Genome Integrity in Tunisian Cervical Cancer Patients","volume":"43","author":"Kala","year":"2012","journal-title":"Braz. J. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2017.10.005","article-title":"Association Between Epstein-Barr Virus (EBV) and Cervical Carcinoma: A meta-analysis","volume":"148","author":"Neto","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Blanco, R., Carrillo-Beltran, D., Osorio, J.C., Calaf, G.M., and Aguayo, F. (2020). Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Cervical Cancer: Epidemiology, Mechanisms and Perspectives. Pathogens, 9.","DOI":"10.3390\/pathogens9090685"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ebrahim, F., Rasizadeh, R., Sharaflou, S., Aghbash, P.S., Shamekh, A., Jafari-Sales, A., and Baghi, H.B. (2024). Coinfection of EBV with Other Pathogens: A Narrative Review. Front. Viorol., 4.","DOI":"10.3389\/fviro.2024.1482329"},{"key":"ref_92","first-page":"134","article-title":"A Population-based Seroepidemiological Study of Cervical Cancer","volume":"54","author":"Dillner","year":"1994","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1590\/S1676-24442010000500011","article-title":"Investigation of the LMPEBV and Co-infection by HPV in Genital Lesions of Patients Infected or Not by HIV","volume":"46","author":"Rodrigues","year":"2010","journal-title":"J. Bras. Patol. Med. Lab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1128\/JVI.73.5.4481-4484.1999","article-title":"The Proto-oncogene c-myc is a Direct Target of Epstein-Barr Virus Nuclear Antigen 2","volume":"73","author":"Kaiser","year":"1999","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Sausen, D.G., Basith, A., and Muqeemuddin, S. (2023). EBV and Lymphomagenesis. Cancers, 15.","DOI":"10.3390\/cancers15072133"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Cui, X., and Snapper, C.M. (2021). Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-associated Diseases. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.734471"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/aol-21-33","article-title":"From pathobiology to targeted treatment in Epstein Barr virus related T cell and Natural Killer cell lymphoproliferative diseases","volume":"5","author":"Glover","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00430-018-0570-1","article-title":"Molecular Mechanisms of EBV-driven Cell Cycle Progression and Oncogenesis","volume":"208","author":"Yin","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/cmr.00022-23","article-title":"HIV-associated Cancers and Lymphoproliferative Disorders Caused by Kaposi Sarcoma Herpes and Epstein-Barr Viruses","volume":"37","author":"Lurain","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"200246","DOI":"10.1016\/j.tvr.2022.200246","article-title":"The Oncogenic Gamma Herpes Viruses Epstein-Barr Virus (EBV) and Kaposi\u2019s Sarcoma-associated Herpes Virus (KSHV) Hijack Retinoic Acid-inducible Gene I (RIG-I) Facilitating Both Viral and Tumour Immune Evasion","volume":"14","author":"Nash","year":"2022","journal-title":"Tumour Virus Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12935-021-01793-3","article-title":"Signaling Pathways of EBV-induced Oncogenesis","volume":"21","author":"Luo","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Rosemarie, Q., and Sugden, B. (2022). Epstein-Barr Virus: How its Lytic Phase Contributes to Oncogenesis. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111824"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cdd.2008.14","article-title":"Viral Pro-survival Proteins Block Separate Stages in Bax Inactivation but Changes in Mitochondrial Ultrastructure Still Occur","volume":"15","author":"Cross","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1128\/JVI.72.10.8392-8395.1998","article-title":"Suppression of c-myc-induced Apoptosis by the Epstein-Barr Virus Gene Product BHRF1","volume":"72","author":"Fanidi","year":"1998","journal-title":"J. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Zelazowska, M.A., McBride, K., and Krug, L.T. (2020). Dangerous Liaisons: Gammaherpesvirus Subversion of the Immunoglobulin Repertoire. Viruses, 12.","DOI":"10.3390\/v12080788"},{"key":"ref_106","unstructured":"Tilakarratne, W.M., and Lewis, J.S. (2023). Nasopharyngeal Carcinoma. WHO Classification of Head and Neck Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/52."},{"key":"ref_107","first-page":"90","article-title":"Nasopharyngeal Carcinoma Incidence and Mortality in China, 2013","volume":"36","author":"Wei","year":"2017","journal-title":"Clin. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of Plasma Epstein-Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N. Eng. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Su, W., Hildesheim, A., and Chang, Y. (2013). Human Leukocyte Antigens and Epstein-Barr Virus-associated Nasopharyngeal Carcinoma: Old Association Offers New Clues into the Role of Immunity in Infection-associated Cancers. Front. Oncol., 3.","DOI":"10.3389\/fonc.2013.00299"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ng.601","article-title":"A Genome-wide Association Study of Nasopharyngeal Carcinoma Identifies three New Susceptibility Loci","volume":"42","author":"Bei","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41467-021-24348-6","article-title":"Whole-Genome Profiling of Nasopharyngeal Carcinoma Reveals Viral-Host Co-operation in Inflammatory NF-KB Activation and Immune Escape","volume":"12","author":"Bruce","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_112","unstructured":"Carneiro, F., Fukayama, M., Grabsch, H.I., and Yasui, W. (2019). Gastric Adenocarcinoma. WHO Classification of Digestive System Tumours, IARC. [5th ed.]."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Nishikawa, J., Iizasa, H., Yoshiyama, H., Shimokuri, K., Kobayashi, Y., Sasaki, S., Nakamura, M., Yanai, H., Sakai, K., and Suehiro, Y. (2018). Clinical Importance of Epstein-Barr Virus-associated Gastric Cancer. Cancers, 10.","DOI":"10.3390\/cancers10060167"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10120-021-01215-3","article-title":"Landscape of EBV-positive Gastric Cancer","volume":"24","author":"Saito","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Park, J.H., Cho, H.J., Seo, J., Park, K.B., Kwon, Y.H., Bae, H.I., Seo, A.N., and Kim, M. (2023). Genetic Landscape and PD-L1 Expression in Epstein-Barr Virus-associated Gastric Cancer According to the Histological Pattern. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-45930-6"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Salnikov, M.Y., MacNeil, K.M., and Mymryk, J.S. (2024). The Viral etiology of EBV-associated Gastric Cancers Contributes to their Unique pathology, Clinical Outcomes, Treatment Responses and Immune Landscape. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1358511"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/modpathol.2016.202","article-title":"Overexpression of PD-L1 in Cancer Cells and PD-L1+ Immune Cells in Epstein-Barr Virus-associated Gastric Cancer, the Prognostic Implications","volume":"30","author":"Saito","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_118","unstructured":"Travis, W.D., and Chan, J.K.C. (2021). Lymphoepithelial Carcinoma of the Lung. WHO Classification of Thoracic Tumours, IARC. [5th ed.]."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/PAS.0000000000001173","article-title":"Epstein-Barr Virus-associated pulmonary Carcinoma: Proposing an Alternative Term and Expanding the Histologic Spectrum of Lymphoepithelioma-like Carcinoma of the Lung","volume":"43","author":"The","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00000478-200206000-00004","article-title":"New Aspects in Clinicopathologic and Oncogene Studies of 23 Pulmonary Lymphoepithelioma-like Carcinomas","volume":"26","author":"Chang","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13027-023-00497-9","article-title":"Detection of Epstein-Barr Virus Infection in Thymic Epithelial Tumors by Nested PCR and Epstein-Barr-encoded RNA ISH","volume":"18","author":"Zhao","year":"2023","journal-title":"Infect. Agent. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0046-8177(93)90031-B","article-title":"Study of Epstein-Barr Virus early RNA1 (EBER1) Expression by InSitu Hybridization in Thymic Epithelial Tumors of Chinese Patients in Taiwan","volume":"24","author":"Wy","year":"1993","journal-title":"Hum. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13027-019-0254-5","article-title":"Association Between Epstein-Barr Virus and Thymic Epithelial Tumors: A Systematic Review","volume":"14","author":"Zhang","year":"2019","journal-title":"Infect. Agent. Cancer"},{"key":"ref_124","unstructured":"Chan, J.K.C., Chalabreysse, L., Mukai, K., and Tateyama, H. (2021). Lymphoepithelial Carcinoma of the Thymus. WHO Classification of Thoracic Tumours, IARC. [5th ed.]."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/JTO.0000000000000269","article-title":"Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors","volume":"9","author":"Huang","year":"2014","journal-title":"Thorac. Oncol."},{"key":"ref_126","unstructured":"Oh, G., Alaggio, R., Chan, J.K.C., and Schuh, A. (2024). Burkitt Lymphoma. WHO Classification of Hematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"101662","DOI":"10.1016\/j.canep.2019.101662","article-title":"Childhood Cancer: Estimating Regional and Global ncidence","volume":"71","author":"Johnston","year":"2021","journal-title":"Cancer Epidemiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/bjh.17922","article-title":"Epstein-Barr Virus Positivity as a Defining Pathogenetic Feature of Burkitt Lymphoma Subtypes","volume":"196","author":"Leoncini","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","article-title":"Genome-wide Discovery of Somatic Coding and Noncoding Mutations in Pediatric Endemic and Sporadic Burkitt Lymphoma","volume":"133","author":"Grande","year":"2019","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2015.07.019","article-title":"Plasmodium Infection Promotes Genomic Instability and AID-dependent B Cell Lymphoma","volume":"162","author":"Robbiani","year":"2015","journal-title":"Cell"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QAI.0000000000000946","article-title":"Evolution of HIV-associated Lymphoma over 3 Decades","volume":"72","author":"Ramaswami","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/s41379-020-0608-y","article-title":"Correction: Frequent Traces of EBV Infection in Hodgkin and non-Hodgkin Lymphomas Classified as EBV-negative by Routine methods: Expanding the Landscape of EBV-related Lymphomas","volume":"33","author":"Mundo","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Ng, C.S., and Qin, J.L. (2025). New Facets of Hematolymphoid Eponymic Diseases. Lymphatics, 3.","DOI":"10.20944\/preprints202502.0943.v1"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.hoc.2019.04.001","article-title":"Burkitt Lymphoma and other High-grade-B-cell Lymphomas with or without MYC, BCL2 and\/or BCL6 Rearrangements","volume":"33","author":"Alsharif","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_135","unstructured":"Gujral, S., Siebert, R., and de Jong, D. (2024). Classic Hodgkin Lymphoma. WHO Classification of Haematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and reed-Sternberg Cells in Hodgkin\u2019s Disease represent the Outgrowth of a Dominant Tumor Clone Derived From (Crippled) Germinal Center B Cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V","article-title":"Nasal T-cell Lymphoma Causally Associated with Epstein-Barr Virus: Clinicopathologic, Phenotypic and Genotypic Studies","volume":"77","author":"Harabuchi","year":"1996","journal-title":"Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","article-title":"NK\/T-cell Lymphoma","volume":"35","author":"Wang","year":"2021","journal-title":"Leukemia"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2003-12-4197","article-title":"Quantitation of Circulating Epstein-Barr Virus (EBV) DNA in the Diagnosis and Monitoring of Natural Killer Cell and EBV-positive Lymphomas in Immunocompetent Patients","volume":"104","author":"Au","year":"2004","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3324\/haematol.2021.280003","article-title":"Immune Pathway Upregulation and Lower Genomic Instability Distinguish EBV-positive nodal T\/NK-cell Lymphoma from ENKTL and PTCL-NOS","volume":"107","author":"Wai","year":"2022","journal-title":"Haematologica"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdp064","article-title":"Epstein-Barr Virus-associated Lymphoproliferative Disease in Non-immunocompromised Hosts: A Status Report and Summary of an International Meeting, 8\u20139 September 2008","volume":"20","author":"Cohen","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41408-017-0021-z","article-title":"Aggressive NK-cell Leukemia: Clinical Subtypes, Molecular Features and Treatment Outcomes","volume":"7","author":"Tang","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/PAS.0000000000001632","article-title":"New Clinicopathologic Scenarios of EBV+ Inflammatory Follicular Dendritic Cell sarcoma. Report of 9 Extrahepatosplenic Cases","volume":"45","author":"Jiang","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00000478-200106000-00003","article-title":"Inflammatory Pseudotumor-like Follicular Dendritic Cell Tumor","volume":"25","author":"Cheuk","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/PAS.0000000000002011","article-title":"Challenges in the Diagnosis of Epstein-Barr Virus-positive Inflammatory Follicular Dendritic Cell Sarcoma","volume":"47","author":"Li","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_146","unstructured":"de Jong, D., Siebert, R., Alaggio, R., and Coupland, S.E. (2024). EBV-mucocutaneous Ulcer. WHO Classification of Haematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"ref_147","unstructured":"Oh, G., and de Jong, D. (2024). Lymphomatoid Granulomatosis. WHO Classification of Haematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"ref_148","unstructured":"Oh, G., and Chan, J. (2024). EBV-positive Diffuse Large B-cell Lymphoma. WHO Classification of Haematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"ref_149","unstructured":"Oh, G., de Jong, D., and Dave, S.S. (2024). Plasmablastic Lymphoma. WHO Classification of Haematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Cui, X., Cao, Z., Ishikawa, Y., Cui, S., Imadome, K., and Snapper, C.M. (2021). Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicits High Titers of neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge. Vaccines, 9.","DOI":"10.3390\/vaccines9030285"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II Studies to Evaluate Safety and Immunogenicity of a Recombinant gp350 Epstein-Barr Virus Vaccine in Healthy Adults","volume":"25","author":"Moutschea","year":"2007","journal-title":"Vaccine"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1016\/j.vaccine.2015.09.093","article-title":"recent Advances in recombinant Protein-based Malaria Vaccines","volume":"33","author":"Draper","year":"2015","journal-title":"Vaccine"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(24)01608-8","article-title":"Prophylactic Vaccines against Epstein-Barr Virus","volume":"404","author":"Zhong","year":"2024","journal-title":"Lancet"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(24)01082-1","article-title":"Therapeutic Vaccines for Epstein-Barr Virus: A Way Forward","volume":"403","author":"Li","year":"2024","journal-title":"Lancet"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cti.2015.4","article-title":"Epstein-Barr Virus Vaccines","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/07448481.2020.1726927","article-title":"Epstein-Barr Virus Infection Status Among First Year Undergraduate University Students","volume":"70","author":"Choi","year":"2020","journal-title":"J. Am. Coll. Health"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of Herpes-like DNA Sequences in AIDS-associated Kaposi\u2019s Sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/CMR.15.3.439-464.2002","article-title":"Spectrum of Kaposi\u2019s Sarcoma-associated Herpesvirus, or Human Herpesvirus 8, Diseases","volume":"15","author":"Ablashi","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi Sarcoma","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/QCO.0b013e3283486d04","article-title":"Human Herpesvirus 8-associated Neoplasms: The Roles of Viral Replication and Antiviral Treatment","volume":"24","author":"Gantts","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1440-1827.2001.01266.x","article-title":"HHV-8 Infection Status of AIDS-unrelated and AIDS-associated Multicentric Castleman Disease","volume":"51","author":"Suda","year":"2001","journal-title":"Pathol. Int."},{"key":"ref_162","unstructured":"De Jong, D., Naresh, K.N., and Chan, J. (2024). KSHV\/HHV8-positive Germinotropic Lymohoproliferative Disorder. WHO Classification of Haematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"ref_163","unstructured":"Douglas, J.l., Gustin, J.K., Moses, A.V., Dezube, B.J., and Pantanowitz, L. (2010). Kaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation. Transl. Biomed., 1."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5858\/arpa.2012-0101-RS","article-title":"Kpaosi Sarcoma","volume":"137","author":"Radu","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.24251","article-title":"Classsic and Extracavity Primary Effusion Lymphoma in 51 HIV-infected Patients from a Single Institution","volume":"91","author":"Guillet","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1177\/1066896920917212","article-title":"Kaposi Sarcoma with Intravascular Primary Effusion Lymphoma in the Skin: A Potential Pitfall in HHV8 Immunohistochemistry Interpretation","volume":"28","author":"Rigby","year":"2020","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_167","unstructured":"De Jong, D., Naresh, K.N., and Chan, J. (2024). Primary Effusion Lymphoma. WHO Classification of Haematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/publications.iarc.who.int\/637."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cncy.22344","article-title":"Human Herpes-8-positive Primary Effusion Lymphoma in HIV-negative Patients: Single Institution Case Series with a Multidisciplinary Characterization","volume":"129","author":"Rossi","year":"2021","journal-title":"Cancer Cytopathol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/dc.20432","article-title":"Serous Effusions in Malignant Lymphomas: A Review","volume":"34","author":"Das","year":"2006","journal-title":"Diagn. Cytopathol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","article-title":"Yiral, Immunologic, and Clinical Features of Primary Effusion Lymphoma","volume":"133","author":"Lurain","year":"2019","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.coviro.2013.05.012","article-title":"Kaposi Sarcoma Associated Herpesvirus Pathogenesis (KSHV)\u2014An Update","volume":"3","author":"Dittmer","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"20160275","DOI":"10.1098\/rstb.2016.0275","article-title":"Kaposi Sarcoma Virus Pathogenesis","volume":"372","author":"Mariggio","year":"2017","journal-title":"Philos. Trans. R. Soc. B"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.yexmp.2009.07.001","article-title":"The inflammatory Component of Kaposi Sarcoma","volume":"87","author":"Pantanowitz","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng1383","article-title":"Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma\u2013associated herpesvirus","volume":"36","author":"Hong","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01830024","article-title":"Idiopathisces Multiples Pigmentsarkom der Haut","volume":"3","author":"Kaposi","year":"1872","journal-title":"Archiv Dermatol. Syphilis"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"E11387","DOI":"10.1073\/pnas.1810128115","article-title":"Epstein-Barr Virus Enhances Genome Maintenance of Kaposi sarcoma-associated Herpesvirus","volume":"115","author":"Bigi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi\u2019s Sarcoma-associated Herpesvirus-like DNA Sequences in AIDS-related Body Cavity-based Lymphoma","volume":"4","author":"Cesarmann","year":"1995","journal-title":"N. Eng. J. Med."},{"key":"ref_178","unstructured":"De Jong, D., Naresh, K.N., and Chan, J. (2024). KSH\/HHV8-positive Diffuse Large B-cell Lymphoma. WHO Classification of Haematolymphoid Tumours, IARC. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1128\/JVI.01334-09","article-title":"Early Events in Kaposi\u2019s Sarcoma-associated Herpesvirus Infection of Target Cells","volume":"84","author":"Chandran","year":"2010","journal-title":"J. Virol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1016\/j.vaccine.2019.04.071","article-title":"A Multivalent Kaposi Sarcoma-associated Herpesvirus-like Particle Vaccine Capable of Eliciting High Titres of Neutralizing Antibodies in Immunized rabbits","volume":"37","author":"Mulama","year":"2019","journal-title":"Vaccine"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e00630-19","DOI":"10.1128\/JVI.00630-19","article-title":"Kaposi Sarcoma-associated Herpesvirus Glycoprotein H is Indispensable for Infection of Epithelial, Endothelial and Fibroblast Cell Types","volume":"93","author":"Muniraju","year":"2019","journal-title":"J. Virol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.virol.2011.01.026","article-title":"The Central Repeat Domain 1 of Kaposi\u2019s Sarcoma-associated Herpesvirus (KSHV) Latency Associated-nuclear Antigen (LANA1) Prevents cis HLA Class 1 Peptide Presentation","volume":"412","author":"Kwun","year":"2011","journal-title":"Virology"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Sugden, A.U., Heyes, M., and Sugden, B. (2021). How Epstein-Barr Virus and Kaposi\u2019s Sarcoma-associated Herpesvirus are Maintained Together to transform the Same B-Cell. Viruses, 13.","DOI":"10.3390\/v13081478"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Boui, M., Rieble, L., and Munz, C. (2022). Co-infection of the Epstein-Barr Virus and the Kaposi Sarcoma-associated Herpesvirus. Viruses, 4.","DOI":"10.3390\/v14122709"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Julius, P., Karg, G., Siyumbwa, S., Musumali, J., Tso, F.Y., Ngalamika, O., Kaile, T., Maate, F., Moonga, P., and West, J.T. (2023). Co-infection and Co-localization of Kaposi Sarcoma-associated Herpesvirus and Epstein-Barr Virus in HIV-associated Kaposi Sarcoma: A Case Report. Front. Cell Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1270935"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0196-0644(94)70181-4","article-title":"HIV: Virology and Mechanisms of Disease","volume":"24","author":"King","year":"1994","journal-title":"Ann. Emerg. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mai.2002.126226","article-title":"Molecular Virology and Immunology of HIV Infection","volume":"110","author":"Chinen","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_188","unstructured":"Centers for Disease Control (CDC) (1981). Kaposi\u2019s Sarcoma and Pneucystits Pneumonia Among Homosexual Men\u2014New York City and California. MMWR Morb. Mortal. Wkly. Rep., 30, 305\u2013308."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated Cancers and Related Diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N. Eng. J. Med."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Omar, A., Marques, N., and Crawfood, N. (2024). Cancer and HIV: The Molecular Mechanisms of the Deadly Duo. Cancers, 16.","DOI":"10.3390\/cancers16030546"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/2147912","article-title":"The Question of HIV Vaccine: Why is a Solution Not Yet Available?","volume":"2024","author":"Libera","year":"2024","journal-title":"J. Immunol. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"12992","DOI":"10.1038\/ncomms12992","article-title":"Genomic and Oncogenic Preference of HBV Integration in Hepatocellular Carcinoma","volume":"7","author":"Zhao","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Nevola, R., Beccia, D., Rosato, V., Ruocco, R., Mestrocinque, D., Villani, A., Perillo, P., Imbriani, S., Delle Femine, A., and Criscuolo, L. (2023). HBV Infectionand Host Interaction: The Role in Viral Persistence and Oncogenesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087651"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Zhang, M., Chen, H., Liu, H., and Tang, H. (2024). The Impact of Integrated Hepatitis B Virus DNA on Oncogenesis and Anti-viral Therapy. Biomarkers Res., 12.","DOI":"10.1186\/s40364-024-00611-y"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1002\/mog2.60","article-title":"Novel Insights into HBV-Hepatocellular Carcinoma at Single-Cell Swquencing","volume":"2","author":"Yin","year":"2023","journal-title":"MedComm-Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Flores, J.F., Thompson, A.J., Ryan, M., and Howed, J. (2022). The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines, 10.","DOI":"10.3390\/vaccines10050793"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular Carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, Progress and Challenges to Hepatitis C Vaccine Development","volume":"156","author":"Baily","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Virzi, A., Suarez, A.A.R., Baumert, T.F., and Lupberger, J. (2018). Oncogenic Signaling Induced by HCV Infection. Viruses, 10.","DOI":"10.3390\/v10100538"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdx635","article-title":"From Hepatitis C Virus Infection to B-cell Lymphoma","volume":"29","author":"Couronne","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"101423","DOI":"10.1016\/j.coviro.2024.101423","article-title":"Hepatitis C Virus and Hepatocellular Carcinoma: Carcinogenesis in the Era of Direct-acting Anti-virals","volume":"67","author":"Fiehu","year":"2024","journal-title":"Curr. Opin. Virol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13027-024-00606-2","article-title":"From Viruses to Cancer: Exploring the Role of the Hepatitis C Virus NS3 Protein in Carcinogenesis","volume":"19","author":"Martineau","year":"2024","journal-title":"Inf. Agents Cancer"},{"key":"ref_203","first-page":"394","article-title":"lobal Cancer Statistics 2018, GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2010-S4-14","article-title":"The Etiology of Hepatocellular Carcinoma and Consequences for Treatment","volume":"15","author":"Sanyal","year":"2010","journal-title":"Oncologist"},{"key":"ref_205","unstructured":"Shirmacher, P. (2019). Hepatocellular Carcinoma. WHO Classification of Digestive System Tumours, IARC. [5th ed.]."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/his.13520","article-title":"Data Set for Reporting of Intrahepatic Cholangiocarcinoma, Perhilar Cholangiocarcinoma and Hepatocellular Carcinoma: Recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"73","author":"Burt","year":"2018","journal-title":"Histopathology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4161\/hv.34306","article-title":"Hepatitis B Vaccination","volume":"11","author":"Romano","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e2128652","DOI":"10.1001\/jamanetworkopen.2021.28652","article-title":"Immunogenicity and Safety of a 3-antigen Hepatitis B Vaccine Vs a Single-antigen Hepatitis B Vaccine","volume":"4","author":"Vasikari","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-year Follow Up Study","volume":"101","author":"Chang","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7774\/cevr.2013.2.2.76","article-title":"Paths Toward Hepatitis B Immunization in South Korea and Taiwan","volume":"2","author":"Chen","year":"2013","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/aob.2017.04.02","article-title":"Chronic and Occult Hepatitis B Virus Infection in the Vaccinated Chinese Population","volume":"2","author":"Li","year":"2017","journal-title":"Ann. Blood"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"215652","DOI":"10.1016\/j.canlet.2022.215652","article-title":"Long Term Outcome of Prevention of Liver Cancer by Hepatitis B Vaccine: Results from an RCT with 37 Years","volume":"536","author":"Cao","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1017\/S095026882300002X","article-title":"Hepatitis B Burden and Population Immunity in a High Endemicity City\u2014A Geographically Random Household Epidemiology Study for Evaluating Achievability of Elimination","volume":"151","author":"Wong","year":"2022","journal-title":"Epidemiol. Infect."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Shoukry, N.H. (2018). Hepatitis C Vaccines, ntibodies, and T Cells. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01480"},{"key":"ref_215","first-page":"26698","article-title":"Minicircle-based Vaccine Induces Potent t-cell and antibody Responses Against Hepatitis C Virus","volume":"14","author":"Czarnota","year":"2024","journal-title":"Nat. Sci. Rep."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9270(00)02167-5","article-title":"Hepatocellular Carcinoma in HIV-infected Patients with Chronic Hepatitis C","volume":"96","author":"Rodriguez","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/cid\/ciw380","article-title":"Trends inIncidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals from 2001 to 2014: A Multicohort Study","volume":"63","author":"Glaerde","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/jgid.jgid_211_23","article-title":"Coinfection of hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-analysis","volume":"16","author":"Awadh","year":"2024","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1665-2681(19)30803-8","article-title":"Hepatocellular Carcinoma in Chronic HBV-HCV Coinfection is Correlated to Fibrosis and Disease Duration","volume":"14","author":"Zampino","year":"2015","journal-title":"Ann. Hepatol."},{"key":"ref_220","first-page":"18","article-title":"Hepatitis C Virus\/ Hepatitis B Virus Coinfection: Current Perspectives","volume":"1","author":"Maqsood","year":"2023","journal-title":"Antiviral Ther."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"224Mehershanhi, S., Haider, A., Kandhi, S., Sun, H., and Patel, H. (2022). Prevalence of Hepatocellular Carcinoma in HIV Patients Coinfected or TripleInfected with Hepatitis B and Hepatitis C in a Community Hospital in South Bronx. Cureus, 14, e26089.","DOI":"10.7759\/cureus.26089"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.1152586","article-title":"Clonal Integration of Polyomavirus in Human Merkel Cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.virol.2012.09.029","article-title":"Merkel Cell Polyomavirus\u2014A Newly Discovered Human Virus with Oncogenic Potential","volume":"5","author":"Spurgeon","year":"2013","journal-title":"Virology"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Stilling, S., Kreuter, A., Gambichler, T., Meyer, T., Stockfleth, E., and Wieland, U. (2022). Epidemiology of Merkel Cell Polyomavirus Infection and Merkel Cell Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14246176"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"200232","DOI":"10.1016\/j.tvr.2021.200232","article-title":"Merkel Cell Polyomavirus and Associated Merkel Cell Carcinoma","volume":"13","author":"Yang","year":"2022","journal-title":"Tumor Virus Res."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"20160276","DOI":"10.1098\/rstb.2016.0276","article-title":"Merkel Cell Polyomavirus and Merkel Cell carcinoma","volume":"372","year":"2017","journal-title":"Philos. Trans. R. Soc. B"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yin, C., Lin, Z., Yan, Z., and Wang, J. (2025). Merkel Cell Polyomavirus Co-infectionin HIV\/AIDS Individuals: Clinical Diagnosis, Consequences and Treatments. Pathogens, 14.","DOI":"10.3390\/pathogens14020134"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pathol.2024.09.019","article-title":"Merkel Cell Carcinoma in Taiwan: A Subset is Chronic Arsenicism-related, and the Merkel Cell Polyomavirus-negative Cases Are Pathologically Distinct from Virus-related Cases with a Poorer Outcome","volume":"57","author":"Liu","year":"2025","journal-title":"Pathology"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41541-021-00382-9","article-title":"Development of a Therapeutic Vaccine Targeting Merkel Cell Polyomavirus Capsid Protein VP1 Against Merkel Cell Carcinoma","volume":"6","author":"Xu","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"s2637","DOI":"10.1200\/JCO.2024.42.16_suppl.2637","article-title":"Development of an mRNA Therapeutic Vaccine for Virally Driven Merkel Cell Carcinoma","volume":"42","author":"Frey","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Gambichler, T., Schrama, D., Kapynen, R., Weyer-Fahlbusch, S.S., Becker, J.C., Susok, L., Kreppel, F., and Abu Rached, N. (2024). Current Progress in Vaccines Against Merkel Cell Carcinoma: A Narrative Review and Update. Vaccines, 12.","DOI":"10.3390\/vaccines12050533"},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Rosean, C.B., Leyder, E.C., Hamilton, J., Carter, J.J., Galloway, D.A., Koelle, D.M., Nghiem, P., and Heiland, T. (2023). LAMP1 Targeting of the Large T Antigen of Merkel Cell Polyomavirus Results in Potent CD4 T Cell Responses and Tumor Inhibition. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1253568"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.vaccine.2011.12.072","article-title":"Development of a DNA Vaccine Targeting Merkel Cell Polyomavirus","volume":"30","author":"Zeng","year":"2012","journal-title":"Vaccine"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(02)07668-7","article-title":"Merkel Cell Carcinoma and HIV Infection","volume":"359","author":"Engels","year":"2002","journal-title":"Lancet"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/QAD.0b013e328340a19c","article-title":"Merkel Cell carcinoma Associated with HIV: Review of 14 Patients","volume":"25","author":"Izikson","year":"2011","journal-title":"AIDS"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"101594","DOI":"10.1016\/j.bjid.2021.101594","article-title":"Pathogenesis of HTLV-1 Infection and Progression Biomarkers: An Overview","volume":"25","author":"Brites","year":"2021","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Foriani, G., Shallak, M., Accolla, R.S., and Romanelli, M.G. (2021). HTLV-1 Infection and Pathogenesis: New Insights from Cellular and animal Models. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158001"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(20)30328-5","article-title":"Human T-cell Lymphotropic Virus Type-1: A Life Long Persistent Infection, Yet Never Truly Silent","volume":"21","author":"Hirons","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/CMR.00063-09","article-title":"Epidemiology, treatment and Prevention of Human T-cell Leukemia Virus Type 1-associated Diseases","volume":"23","author":"Goncalves","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_240","first-page":"2299","article-title":"HTLV-1 Persistence and the Oncogenesis of Adult T-cell Leukemia\/Lymphoma","volume":"141","author":"Bangham","year":"2023","journal-title":"Blood"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"100525","DOI":"10.1016\/j.jvacx.2024.100525","article-title":"HTLV-1 Vaccination Landscape: Current Development and Challenges","volume":"9","author":"Letafati","year":"2024","journal-title":"Vaccine X"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jcp-2025-210074","article-title":"The Fifth Edition of the WHO Classificationof Mature T Cell. NK Cell and Stroma-derived Neoplasm","volume":"78","author":"Attygalle","year":"2025","journal-title":"J. Clin. Pathol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13302","article-title":"Clinical Outcomes of a Novel Therapeutic Vaccine with Tax Peptide-pulsed Dendritic Cell for Adult T Cell Leukemia\/Lymphoma in a Pilot Study","volume":"169","author":"Suchiro","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"101063","DOI":"10.1016\/j.disamonth.2020.101063","article-title":"SARS 2 human coronavirus (COVID-19, SARS CoV2)","volume":"66","author":"McFee","year":"2020","journal-title":"Dis. Mon."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COV-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"198464","DOI":"10.1016\/j.virusres.2021.198464","article-title":"Immune Characterization and profiles of SARS-CoV-2 Infected Patients Reveals Potential Host Therapeutic Targets and SARS-CoV-2 Oncogenesis Mechanism","volume":"301","author":"Plicard","year":"2021","journal-title":"Virus Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biochi.2023.05.014","article-title":"Possible Cancer-causing Capacity of COVID-19: Is SARS-CoV-2 an Oncogenic Agent?","volume":"213","author":"Jahankani","year":"2023","journal-title":"Biochime"},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Stingi, A., and Crillo, L. (2021). SARS-CoV-2 infection and cancer: Evidence for and against a role of SARS-CoV-2 in cancer onset. Bioessays, 43.","DOI":"10.1002\/bies.202000289"},{"key":"ref_249","first-page":"328","article-title":"The Big Challenge of SARS-CoV-2 Latency: Testes as Reservoir","volume":"156","year":"2020","journal-title":"Gaceto Med. Mex."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"103488","DOI":"10.1016\/j.transci.2022.103488","article-title":"SARS-CoV-2 and Cancer: The Intriguing and Informative Cross-talk","volume":"61","author":"Goubran","year":"2022","journal-title":"Transfus. Apher. Sci."},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Costanzo, M., De Giglio, M.A.R., and Roviello, G.N. (2023). Deciphering the Relationship Between SARS-CoV-2 and Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097803"},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Chia, S.B., Johnson, B.J., Hu, J., Valenca-Pereira, F., Chadeau-Hyam, M., Guntoro, F., Montgomery, H., Boorgula, M.P., Sreekanth, V., and Goodspeed, A. (2025). Respiratory Viral Infections Awaken Metastatic Breast Cancer Cells in Lungs. Nature.","DOI":"10.1038\/s41586-025-09332-0"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"e01276","DOI":"10.14309\/crj.0000000000001276","article-title":"Primary Hepatic EBV-DLBCL Lymphoma in the Setting of COVID-19 Infection","volume":"11","author":"Ismail","year":"2024","journal-title":"ACG Case Rep. J."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1002\/jmv.29849","article-title":"Exploring the Interplay Between Kaposi\u2019s Sarcoma and SARS-CoV-2 Infection. A Case Series and Systematic Review","volume":"96","author":"Pietroluongo","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_255","unstructured":"Pasi, F., Calveri, M.M., Pizzarelli, G., Calabresse, A., Andreoli, M., Bongiovanni, I., Cattaneo, C., and Rignanese, G. (2020). Oncolytic Effect of SARS-CoV-2 in a Patient with NK Lymphoma. Acta Biomed., 91."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjh.17116","article-title":"SARS-CoV-2 Induced Remission of Hodgkin Lymphoma","volume":"192","author":"Challenor","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"e05682","DOI":"10.1002\/ccr3.5682","article-title":"Oncolytic Effect of SARS-CoV-2 in a Patient with Mycosis Fungoides: A Case Report","volume":"10","author":"Ohadi","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"e23937","DOI":"10.1002\/jcla.23937","article-title":"Analysis of COVID-19 Vaccines: Types, Thoughts and Applications","volume":"35","author":"Han","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0264-410X(00)00152-3","article-title":"Intent-to-treat Analysis and Preventive Vaccine Efficacy","volume":"19","author":"Horne","year":"2000","journal-title":"Vaccine"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1191\/0962280204sm356ra","article-title":"Endpoints in Vaccine Trials","volume":"13","author":"Hudgens","year":"2004","journal-title":"Stat. Methods Med. Res."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:34:04Z","timestamp":1760034844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":260,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["vaccines13090911"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13090911","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}